parts of the body. It can also be a starting point for blood clot formation, increasing the risk for adverse events like thrombosis. If aortic aneurysms rupture, survival rate is very low (10-15%).
Aneurysm is characterized by chronic inflammation and degradation of extracellular matrix (ECM) components by proteolytic enzymes like Matrix-Metalloproteases (MMPs). This can lead to inflammatory infiltration in the adventitia, calcification and degeneration of medial elastic lamina. The calcified region has a higher stiffness than the surrounding arterial wall. Initially, aortic aneurysms were considered to be a form of atherosclerosis, but now are characterized as a distinct degenerative disease involving all layers of the vessel wall. The infiltrating cells, including B cells, T cells, mast cells, macrophages, and neutrophils secrete proinflammatory mediators, lead to the acceleration of matrix degradation.
Aneurysms & Stroke
By combining targeting with one or two drugs in nanoparticles, the therapy has been shown to completely reverse aneurysms in lab animals.
Aneurysm is a balloon-like bulge in the aorta caused by thinning and weakening of the vessel wall due to degradation of elastin fiber. It occurs in the abdominal aortic artery, the brain where it leads to stroke, and in other
There is no effective therapy. Watching and waiting with blood pressure control is a standard procedure. Surgical, mostly minimally invasive, interventions are common to treat aneurysms that progress to a dangerous stage. Available repair systems are stent grafts and catheters.
The market for aortic aneurysm repair is expected to exceed 3.4 billion USD by 2023. Key players on the market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers, Abbott, AbbVie Inc., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc.,Sanofi, GlaxoSmithKline Pharmaceuticals Limited and Mylan N.V.